Literature DB >> 29611001

Eosinophilic Granulomatosis With Polyangiitis: Newer Therapies.

Erika P Navarro-Mendoza1, Gabriel J Tobón2,3.   

Abstract

PURPOSE OF REVIEW: Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic disseminated vasculitis associated with extravascular granulomas in patients suffering from asthma and tissue eosinophilia. Current therapies to achieve remission and prevent relapse include glucocorticoids and immunosuppressants like cyclophosphamide. RECENT
FINDINGS: With the right treatment, clinical prognosis is favorable, so concerted efforts have been made in recent years to find new alternatives for treating severe EGPA. Monoclonal antibodies such as omalizumab, rituximab, and mepolizumab are among these new options. This review summarizes the pathogenesis and clinical manifestations of EGPA and critically examines current and emerging therapies.

Entities:  

Keywords:  Churg−Strauss syndrome; Mepolizumab; Omalizumab; Rituximab; Therapeutics

Mesh:

Substances:

Year:  2018        PMID: 29611001     DOI: 10.1007/s11926-018-0736-2

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  54 in total

1.  Churg-Strauss syndrome occurring during omalizumab treatment.

Authors:  Muhammed Bekçibaşı; Sezgin Barutçu; Mustafa Kemal Çelen; Saim Dayan; Salih Hoşoğlu
Journal:  Eur J Rheumatol       Date:  2015-03-31

2.  Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management.

Authors:  Matthieu Groh; Christian Pagnoux; Chiara Baldini; Elisabeth Bel; Paolo Bottero; Vincent Cottin; Klaus Dalhoff; Bertrand Dunogué; Wolfgang Gross; Julia Holle; Marc Humbert; David Jayne; J Charles Jennette; Romain Lazor; Alfred Mahr; Peter A Merkel; Luc Mouthon; Renato Alberto Sinico; Ulrich Specks; Augusto Vaglio; Michael E Wechsler; Jean-François Cordier; Loïc Guillevin
Journal:  Eur J Intern Med       Date:  2015-05-09       Impact factor: 4.487

3.  Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study.

Authors:  Aikaterini Detoraki; Lorena Di Capua; Gilda Varricchi; Arturo Genovese; Gianni Marone; Giuseppe Spadaro
Journal:  J Asthma       Date:  2015-09-17       Impact factor: 2.515

4.  Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.

Authors:  Loïc Guillevin; Christian Pagnoux; Alexandre Karras; Chahera Khouatra; Olivier Aumaître; Pascal Cohen; François Maurier; Olivier Decaux; Jacques Ninet; Pierre Gobert; Thomas Quémeneur; Claire Blanchard-Delaunay; Pascal Godmer; Xavier Puéchal; Pierre-Louis Carron; Pierre-Yves Hatron; Nicolas Limal; Mohamed Hamidou; Maize Ducret; Eric Daugas; Thomas Papo; Bernard Bonnotte; Alfred Mahr; Philippe Ravaud; Luc Mouthon
Journal:  N Engl J Med       Date:  2014-11-06       Impact factor: 91.245

5.  Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy.

Authors:  Christian Pagnoux; Thomas Quéméneur; Jacques Ninet; Elisabeth Diot; Xavier Kyndt; Benoît de Wazières; Jean-Luc Reny; Xavier Puéchal; Pierre-Yves le Berruyer; Olivier Lidove; Philippe Vanhille; Pascal Godmer; Olivier Fain; Daniel Blockmans; Boris Bienvenu; Florence Rollot; Séverine Aït el Ghaz-Poignant; Alfred Mahr; Pascal Cohen; Luc Mouthon; Elodie Perrodeau; Philippe Ravaud; Loïc Guillevin
Journal:  Arthritis Rheumatol       Date:  2015-04       Impact factor: 10.995

6.  Both Th2 and Th17 responses are involved in the pathogenesis of Churg-Strauss syndrome.

Authors:  Bogdan Jakiela; Marek Sanak; Wojciech Szczeklik; Barbara Sokolowska; Hanna Plutecka; Lucyna Mastalerz; Jacek Musial; Andrzej Szczeklik
Journal:  Clin Exp Rheumatol       Date:  2011-05-11       Impact factor: 4.473

7.  Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.

Authors:  Michael E Wechsler; Praveen Akuthota; David Jayne; Paneez Khoury; Amy Klion; Carol A Langford; Peter A Merkel; Frank Moosig; Ulrich Specks; Maria C Cid; Raashid Luqmani; Judith Brown; Stephen Mallett; Richard Philipson; Steve W Yancey; Jonathan Steinfeld; Peter F Weller; Gerald J Gleich
Journal:  N Engl J Med       Date:  2017-05-18       Impact factor: 91.245

Review 8.  Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome.

Authors:  J G Lanham; K B Elkon; C D Pusey; G R Hughes
Journal:  Medicine (Baltimore)       Date:  1984-03       Impact factor: 1.889

9.  Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.

Authors:  Christian Pagnoux; Alfred Mahr; Mohamed A Hamidou; Jean-Jacques Boffa; Marc Ruivard; Jean-Pierre Ducroix; Xavier Kyndt; François Lifermann; Thomas Papo; Marc Lambert; José Le Noach; Mehdi Khellaf; Dominique Merrien; Xavier Puéchal; Stéphane Vinzio; Pascal Cohen; Luc Mouthon; Jean-François Cordier; Loïc Guillevin
Journal:  N Engl J Med       Date:  2008-12-25       Impact factor: 91.245

Review 10.  Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg-Strauss syndrome).

Authors:  Luc Mouthon; Bertrand Dunogue; Loïc Guillevin
Journal:  J Autoimmun       Date:  2014-02-12       Impact factor: 7.094

View more
  2 in total

1.  A Pediatric Case of Relapsing Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab.

Authors:  Mizuho Nara; Masaya Saito; Fumito Abe; Atsushi Komatsuda; Hideki Wakui; Naoto Takahashi
Journal:  Intern Med       Date:  2019-08-06       Impact factor: 1.271

Review 2.  Burden of illness associated with eosinophilic granulomatosis with polyangiitis: a systematic literature review and meta-analysis.

Authors:  Rupert W Jakes; Namhee Kwon; Beth Nordstrom; Rebecca Goulding; Kyle Fahrbach; Jialu Tarpey; Melissa K Van Dyke
Journal:  Clin Rheumatol       Date:  2021-06-23       Impact factor: 2.980

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.